Induced Pluripotent Stem Cells Production Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

Hospitals & Clinics is the fastest growing sector, North America is the largest market

The Global Induced Pluripotent Stem Cells Production Market is anticipated to expand from USD 1.88 Billion in 2025 to USD 3.52 Billion by 2031, demonstrating an 11.02% Compound Annual Growth Rate. Induced pluripotent stem cells (iPSCs) are adult somatic cells that have been genetically reprogrammed to an embryonic-like state, enabling them to differentiate into various cell types for a wide range of therapeutic and research uses. This market growth is largely fueled by the increasing need for regenerative medicines to address chronic diseases, along with the necessity for human-relevant disease models that can reduce dependence on animal testing in drug discovery. Evidence of this dynamic growth environment includes the cell and gene therapy sector's support of over 2,500 active clinical trials worldwide in 2024, as reported by the Alliance for Regenerative Medicine, which in turn generates significant demand for high-quality iPSC production.

Nevertheless, the industry encounters a substantial obstacle concerning the scalability of its manufacturing processes. Achieving clinical-grade cells necessitates rigorous quality control and reproducibility, which proves challenging to sustain at commercial production levels. This production bottleneck leads to elevated manufacturing costs and inconsistencies, complicating regulatory approval and impeding the widespread therapeutic adoption essential for mass market expansion.

Market Drivers

The primary driver behind the Global Induced Pluripotent Stem Cells Production Market's growth is the broadening application of regenerative medicine and tissue engineering. As iPSC-derived therapies advance from preclinical research to later-stage human clinical trials, there is a heightened demand for consistent, clinical-grade cell lines, especially for addressing neurodegenerative and metabolic conditions. This progress is underscored by notable developments in commercial pipelines; for example, Bayer AG announced in January 2025 its intention to start a pivotal Phase III clinical trial for bemdaneprocel, an iPSC-based therapy targeting Parkinson's disease. Additionally, the increasing maturity of the sector is clear within the diabetes therapeutic area, with Vertex Pharmaceuticals reporting in August 2025 that it is on schedule to finalize enrollment and dosing in the Phase 3 segment of its worldwide study for zimislecel, a fully differentiated islet cell therapy.

Simultaneously, a significant rise in both government funding and private investment is speeding up the expansion of iPSC manufacturing capabilities to satisfy this clinical demand. Capital is increasingly being channeled into biotechnology companies focused on developing proprietary mass-production platforms designed to overcome critical issues related to cost and consistency. A case in point is TreeFrog Therapeutics, which in May 2025 secured €30 million in financing from the European Investment Bank to enhance its biomimetic cell therapy pipeline and manufacturing infrastructure. This injection of capital enables companies to establish resilient supply chains and automated production facilities, directly tackling the manufacturing hurdles necessary to support the growing commercial market.

Market Challenges

A major impediment to the growth of the Global Induced Pluripotent Stem Cells Production Market is the challenge of manufacturing process scalability. While the research pipeline is extensive, moving from small-scale laboratory experiments to commercial mass production is complicated by technical difficulties, particularly in ensuring cell consistency, sterility, and genomic stability when operating at larger volumes. This bottleneck compels manufacturers to depend on manual, labor-intensive methods, which substantially raise the Cost of Goods Sold (COGS) and introduce variations between batches. Such inefficiencies complicate the Chemistry, Manufacturing, and Controls (CMC) data needed for regulatory filings, often causing approval delays and preventing therapies from reaching a price point accessible for widespread healthcare adoption.

The significant gap in commercialization is further emphasized by the contrast between clinical trial activity and actual market success. In 2025, approximately 75% of worldwide cell and gene therapy revenue originated from fewer than 10 commercial products, as reported by the Alliance for Regenerative Medicine. This figure highlights that despite numerous active clinical trials, the failure to develop cost-effective, reproducible manufacturing platforms means most potential therapies cannot achieve commercial viability. As a result, the market continues to be limited to expensive, specialized treatments, rather than attaining the broad availability necessary for widespread market expansion.

Market Trends

A major transformative trend in the Global Induced Pluripotent Stem Cells Production Market is the incorporation of artificial intelligence (AI) for process optimization, which is fundamentally changing manufacturing approaches. Developers are increasingly utilizing machine learning algorithms to examine cellular characteristics and forecast differentiation results, thereby tackling the persistent problem of batch-to-batch inconsistency inherent in manual production. This integration of technology facilitates real-time quality control and automated purification, significantly boosting the output of viable clinical-grade cells. The strong push for this trend is exemplified by substantial federal funding for AI-driven biomanufacturing; for example, Cellino Biotech received $25 million from the Advanced Research Projects Agency for Health (ARPA-H) in September 2024 to further develop its NEBULA platform, an AI-guided laser editing system designed to automate the scalable production of personalized iPSCs.

Concurrently, the industry is making a crucial transition towards allogeneic, "off-the-shelf" iPSC platforms, aiming to bypass the high costs and logistical difficulties linked with autologous therapies. By employing universal donor cell lines engineered to avoid immune rejection, manufacturers can produce large quantities suitable for treating many patients, essentially treating these cells as a standardized pharmaceutical product rather than a customized service. This strategic shift is spurring consolidation and acquisitions among leading market participants seeking to establish strong "universal" cell banks. An illustration of this is Century Therapeutics' acquisition of Clade Therapeutics for $35 million in April 2024, specifically to integrate its proprietary Allo-Evasion technology and broaden its pipeline of preclinical off-the-shelf iPSC-derived treatments for cancer and autoimmune diseases.

Key Market Players

• Lonza Group
• Axol Biosciences Ltd.
• Evotec SE
• Hitachi Ltd.
• Reprocells Inc.
• Fate Therapeutics Inc.
• Thermo Fisher Scientific, Inc.
• Merck KgaA
• Stemcellsfactory III
• Applied Stemcells Inc.

Report Scope

In this report, the Global Induced Pluripotent Stem Cells Production Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Induced Pluripotent Stem Cells Production Market, by Process:

• Manual iPSC Production Process
• Automated iPSC Production Process

Induced Pluripotent Stem Cells Production Market, by Product:

• Instruments/ Devices
• Automated Platforms
• Consumables & Kits
• Services

Induced Pluripotent Stem Cells Production Market, by Application:

• Drug Development and Discovery
• Regenerative Medicine
• Toxicology Studies
• Others

Induced Pluripotent Stem Cells Production Market, by End-user:

• Research & Academic Institutes
• Biotechnology & Pharmaceutical Companies
• Hospitals & Clinics

Induced Pluripotent Stem Cells Production Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Induced Pluripotent Stem Cells Production Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.